Hennion & Walsh Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Hennion & Walsh Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-43,316	Closed	-$4.42M	–	847
2023 Q2	$4.42M	Sell	43,316 -12,888	-23%	-$1.22M	0.26%	88
2023 Q1	$5.11M	Sell	56,204 -1,870	-3%	-$110K	0.31%	76
2022 Q4	$2.21M	Sell	58,074 -12,710	-18%	-$437K	0.14%	192
2022 Q3	$1.78M	Buy	70,784 +4,268	+6%	+$118K	0.12%	209
2022 Q2	$2.02M	Buy	66,516 +18,333	+38%	+$547K	0.13%	199
2022 Q1	$1.58M	Buy	48,183 +5,673	+13%	+$168K	0.08%	256
2021 Q4	$1.12M	Buy	42,510 +2,725	+7%	+$211K	0.06%	331
2021 Q3	$4M	Buy	39,785 +3,700	+10%	+$434K	0.21%	128
2021 Q2	$5.11M	Buy	36,085 +375	+1%	+$42.3K	0.27%	88
2021 Q1	$3.56M	Buy	+35,710	New	+$4.17M	0.21%	121

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Hennion & Walsh Asset Management's RETA Position: Q3 2023 in Review

Hennion & Walsh Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 43,316 shares — an estimated $4.42M sold.

Hennion & Walsh Asset Management first reported a position in RETA in Q1 2021 and held it in 10 quarters. The position peaked at $5.11M in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Hennion & Walsh Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Hennion & Walsh Asset Management sold 43,316 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $4.42M.
Hennion & Walsh Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 10 quarters.
Hennion & Walsh Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $5.11M in Q1 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Hennion & Walsh Asset Management's 13F filing for Q3 2023, filed 27 Oct 2023.